<DOC>
	<DOCNO>NCT02789189</DOCNO>
	<brief_summary>The purpose single arm , phase Ⅱ clinical trail determine safety efficacy nedaplatin combine gemcitabine treatment recurrent metastatic nasopharyngeal carcinoma</brief_summary>
	<brief_title>Nedaplatin Combined With Gemcitabine Treatment Recurrent Metastatic Nasopharyngeal Carcinoma : Single Arm Phase Ⅱ Clinical Trail</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<criteria>biopsy prove nasopharyngeal carcinoma ; stage IVc accord Union International Cancer Control ( UICC ) edition VII , recurrent disease chemotherapy and/or radiotherapy ; 18 year old ; without malignancy ; proper function major organ . allergic nedaplatin and/or gemcitabine ; female within gestation period lactation ; patient receive drug clinical trail within 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>